Full history for every metric is available with a Kvantra account
Third Harmonic Bio, Inc. (THRD)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | 59 | -66 | |||||
| Net profit | $m | - | -13 | -30 | -38 | -31 | 45 | -53 |
| EPS reported | $ | 1.09 | -0.57 | |||||
| Operating cashflow per share | $ | -0.83 | -0.83 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.83 | -0.83 | |||||
| Free cash flow | $m | -35 | -42 | |||||
| Net debt | $m | -285 | -272 | |||||
| Book value equity | $m | 285 | 273 | |||||
| Book value per share | $ | 6.83 | 6.07 | |||||
| Number of shares | m | 41.73 | 44.92 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 9.44 | - | |||||
| P/B LTM | x | 1.51 | 0.89 | |||||
| P/S LTM | x | 0.00 | 5,058.07 | |||||
| P/FCF LTM | x | -12.44 | -5.82 | |||||
| EV/EBITDA LTM | x | -3.25 | 0.44 | |||||
| EV/Sales LTM | x | 0.00 | -600.49 | |||||
| Earnings Yield LTM | % | 10.59% | 20.25% | |||||
| FCF Yield | % | -8.04% | -17.17% | |||||
| Quality | ||||||||
| ROE | % | 15.95% | 16.41% | |||||
| ROIC | % | 20.42% | 20.42% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -94.26% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.76 | -13.89 | |||||
| Net Debt/EBITDA | x | 6.21 | 6.21 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -66.39% | -111.87% | |||||
| Net debt/Equity | x | -1.00 | -1.00 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free